The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.
Marzia Del ReStefania CrucittaFederico PaolieriFederico CucchiaraElena VerzoniFrancesco BloiseRaffaele CiampiChiara MercinelliAnnalisa CapuanoLiberata SportielloAntonia MartinettiGiuseppe ProcopioLuca GalliCamillo PortaSergio BracardaRomano DanesiPublished in: Journal of translational medicine (2022)
The present study demonstrates that cfDNA and TP53 are potential predictive biomarkers of response in mccRCC to be further explored in larger and/or prospective studies.